… NMDA receptors, providing a rationale for its use to treat dyskinesias.   However, memantine is an especially … Neurobehavioral … Complications of Treatment … California … Dyskinesia … United States … Dyskinesia Challenge … Ian Irwin, PhD …

… early stages, chronic treatment leads to the development of dyskinesias or movement abnormalities. These can be very … symptoms of Parkinson’s disease. If we are to prevent these dyskinesias from occurring, it is important to understand … with levodopa treatment. … Complications of Treatment … Dyskinesia … Neuropharmacology … Basal Ganglia … California …

… Objective/Rationale:              The appearance of dyskinesia presents new challenges as a symptom of long-term … of the serotonin neurons have been shown to suppress dyskinesia. Project Description:              In this … serotonin neurons as a target to address levodopa-induced dyskinesia. In particular, we will explore whether increase …

… patients developed postoperative, graft-induced dyskinesias (GID). Our project has four aims: To develop a … dopamine and whether preoperative L-DOPA-induced dyskinesias predispose to GID; To test the hypothesis that … project will thus clarify the conditions that predispose to dyskinesia after intrastriatal transplantation of dopamine …

… upon the research from a prior grant: LRRK2 Activity and Dyskinesia Promising Outcomes of Original Grant: Our … of striatal LRRK2 in the development of levodopa-induced dyskinesia (LID). We found that inhibiting LRRK2 in the … endogenous striatal LRRK2 may be a key regulator of the dyskinesia response to dopaminergic pharmacotherapy. …

… from a prior grant: Role of LRRK2 in Levodopa-induced Dyskinesia Promising Outcomes of Original Grant: … development of drug-induced involuntary movements called dyskinesia. We initially hypothesized that increased LRRK2 activity could worsen dyskinesia, but results from our pre-clinical study showed …